Literature DB >> 20170953

The effect of two point mutations in GDF-5 on ectopic bone formation in a beta-tricalciumphosphate scaffold.

Philip Kasten1, Ingo Beyen, Dirk Bormann, Reto Luginbühl, Frank Plöger, Wiltrud Richter.   

Abstract

The osteoinductivity of human growth-and-differentiation factor-5 (GDF-5) is well established, but a reduced amount of ectopic bone is formed compared to other members of the bone morphogenetic protein (BMP) family like BMP-2. We hypothesized that swap of two BMP-receptor-interacting residues of GDF-5 to amino acids present in BMP-2 (methionine to valine at the sites 453 and 456) may improve the bone formation capacity of the mutant GDF-5. Heterotopic bone formation of a mutant GDF-5 coated beta-TCP carrier was compared to carriers coated with similar amounts (10 microg) of GDF-5 and BMP-2 in SCID mice. Four week explants revealed 6-fold higher ALP activity in the mutant GDF-5 versus the wild type GDF-5 group (p < 0.0001) and 1.4-fold higher levels compared to BMP-2 (p < 0.006). Bone area in histology was significantly higher in mutant GDF-5 versus all other groups at 4 weeks; however, at 8 weeks BMP-2 reached a similar neo-bone formation like mutant GDF-5. Micro-CT evaluation confirmed higher values in the mutant GDF-5 and BMP-2 groups compared to wild type GDF-5. In conclusion, the mutant GDF-5 showed superior bone formation capacity than GDF-5, and a faster induction at similar final outcome as BMP-2. Mutant GDF-5 thus represents a promising new GDF-5 variant for bone regeneration possibly acting via an increased binding affinity to the BMP-type I receptor. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170953     DOI: 10.1016/j.biomaterials.2010.01.109

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  Bone Morphogenetic Protein-Based Therapeutic Approaches.

Authors:  Jonathan W Lowery; Vicki Rosen
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 2.  A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives.

Authors:  Jonathan W Lowery; Brice Brookshire; Vicki Rosen
Journal:  Stem Cells Int       Date:  2016-06-28       Impact factor: 5.443

Review 3.  Ordinary and Activated Bone Grafts: Applied Classification and the Main Features.

Authors:  R V Deev; A Y Drobyshev; I Y Bozo; A A Isaev
Journal:  Biomed Res Int       Date:  2015-11-15       Impact factor: 3.411

4.  A consistent and potentially exploitable response during chondrogenesis of mesenchymal stem cells from osteoarthritis patients to the protein encoded by the susceptibility gene GDF5.

Authors:  Madhushika Ratnayake; Maria Tselepi; Robert Bloxham; Frank Plöger; Louise N Reynard; John Loughlin
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

5.  In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5, BB-1, and BMP-2) from a PLGA Fiber-Reinforced, Brushite-Forming Calcium Phosphate Cement.

Authors:  Francesca Gunnella; Elke Kunisch; Victoria Horbert; Stefan Maenz; Jörg Bossert; Klaus D Jandt; Frank Plöger; Raimund W Kinne
Journal:  Pharmaceutics       Date:  2019-09-03       Impact factor: 6.321

Review 6.  Bone Augmentation for Implant Placement: Recent Advances.

Authors:  Van Viet Dam; Hai Anh Trinh; Dinesh Rokaya; Dinh Hai Trinh
Journal:  Int J Dent       Date:  2022-03-27

Review 7.  Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives.

Authors:  Antalya Ho-Shui-Ling; Johanna Bolander; Laurence E Rustom; Amy Wagoner Johnson; Frank P Luyten; Catherine Picart
Journal:  Biomaterials       Date:  2018-07-11       Impact factor: 12.479

8.  Human chondrocytes respond discordantly to the protein encoded by the osteoarthritis susceptibility gene GDF5.

Authors:  Madhushika Ratnayake; Frank Plöger; Mauro Santibanez-Koref; John Loughlin
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.